新药周观点：映恩B7H3 ADC展现MCRPC领域BIC潜力，后续多个二代IO+ADC数据读出值得期待-20260308

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [6] Core Insights - The report highlights the potential of the B7H3 ADC DB-1311/BNT324 in metastatic castration-resistant prostate cancer (mCRPC), showcasing promising durable efficacy in patients previously treated with Lu-177 [3][21] - Multiple catalysts are anticipated in the sector, including academic conferences and data readouts, with a focus on companies like Betta Pharmaceuticals, InnoCare Pharma, and others [2][20] - The report emphasizes the ongoing clinical trial approvals and applications, indicating a robust pipeline in the biopharmaceutical industry [10][32] Summary by Sections Weekly New Drug Market Review - From March 2 to March 8, 2026, the top five gainers in the new drug sector were: Yihong Pharma (+38.11%), Aosaikang (+33.53%), Deki Pharma (+19.57%), Kaituo Pharma (+8.58%), and Rongchang Bio (+7.33%). The top five losers were: Yongtai Bio (-14.23%), Youzhiyou (-21.27%), Keji Pharma (-23.13%), Xuanzhu Bio (-24.24%), and Baoji Pharma (-34.54%) [1][16] Weekly Focus on Recommended Stocks - The report suggests focusing on stocks with potential overseas data catalysts, such as Betta Pharmaceuticals, InnoCare Pharma, and Hutchison China MediTech. It also highlights companies with high certainty for overseas volume due to MNC certification, including 3SBio, United Laboratories, and Kelun-Biotech [2][20] Weekly New Drug Industry Analysis - In a recent presentation at the 2026 ASCO GU, InnoCare Pharma reported encouraging results for DB-1311 in mCRPC patients, particularly those previously treated with Lu-177, indicating its potential as a leading therapy in this space [3][21] - The report notes that 146 mCRPC patients were included in the study, with a median age of 70 and a median of 4 prior treatment lines [21][22] Weekly New Drug Approval & Acceptance Status - This week, 9 new drug or new indication applications were approved, and 8 new drug or new indication applications were accepted in China [4][26] Weekly New Drug Clinical Application Approval & Acceptance Status - A total of 73 new drug clinical applications were approved, and 52 new drug clinical applications were accepted this week [10][32]